12,372 trials
Non-small Cell Lung Cancer
Primary: Disease-Free Survival (DFS) — 53.8; 43.0 Months
Prostate Cancer · Prostatic Neoplasm · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection of Regional Pelvic Nodal Metastases on a Per Patient…
Hemophilia A
Primary: Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIII — 0; 0 Participants
Attention-Deficit/Hyperactivity Disorder
Primary: Incidence of Adverse Events — 72.3 percentage of subjects
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Among Participants Administered V110 — 18.7; 14.7; 74.8; 74.4 Percentage of Participants
Sleep Disturbance · Craving · Cortisol; Hypersecretion
Primary: Change in Total Sleep Time as Measured by Actigraphy and Sleep Logs Relative to Baseline Over the Course of 7 Days of Treatment With Suvorexant in Substance Use Disorder…
Acute Urticaria
Primary: Extent of Urticaria/Erythema Score (Physician Assessment) — 1.91; 1.74; 1.53; 1.12 units on a scale
Myositis
Primary: Response Rate During Randomized Phase — 3; 1; 5; 2 Participants — p=0.60
Complex Regional Pain Syndrome
Primary: Pain Score — 5.9; 6.0; 6.5; 6.8 score on a scale — p=0.19
Plaque Psoriasis
Primary: Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group) — 1458.03; 1472.68 hr*μg/mL
Epilepsy, Partial
Primary: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period — -66.4; -47.8; -66.4 percentage of change
Rabies · Healthy Volunteers
Primary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL — 100; 100; 100; 100…
Guillain-Barre Syndrome
Primary: Time to First Reaching a Hughes Functional Grade (FG) Score <=1 — 112.0; 168.0 Days — p=0.8938
Respiratory Syncytial Viruses · Lower Respiratory Tract Disease
Primary: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower…
Psoriatic Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 3 — 38.24; 5.88 Percentage of participants — p=<0.0001